MedTrace Logo

Severe Toxicity Free Survival Following Childhood Acute Lymphoblastic Leukemia

NCT05639673 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2023-05-26

No results posted yet for this study

Summary

The goal of this observational study is to quantify the burden of particularly severe, long-term adverse effects in childhood acute lymphoblastic leukemia (ALL) survivors. The adverse effects include 21 severe health conditions recently selected and defined as Severe Toxicities by an international collaboration of ALL consortia.

The main questions the study aims to answer for childhood ALL patients are:

* What is the chance of surviving without any Severe Toxicities during the first 5 years after ALL diagnosis?
* What is the average cumulative burden of different Severe Toxicities during the first 5 years after ALL diagnosis? The study uses standard-care follow-up data for childhood ALL patients from an international collaboration of five ALL consortia from Europe, the US, and Australia.

Conditions

Sponsors & Collaborators

  • Danish Child Cancer Foundation

    collaborator OTHER

  • Aarhus University Hospital

    collaborator OTHER

  • Odense University Hospital

    collaborator OTHER

  • Aalborg University Hospital

    collaborator OTHER

  • Royal Children's Hospital

    collaborator OTHER

  • St. Jude Children's Research Hospital

    collaborator OTHER

  • Princess Maxima Center for Pediatric Oncology

    collaborator OTHER

  • Nordic Society for Pediatric Hematology and Oncology

    collaborator OTHER

  • Medical University of Lodz

    collaborator OTHER

  • Rigshospitalet, Denmark

    lead OTHER

Principal Investigators

  • Kjeld Schmiegelow, DMSc · Rigshospitalet, Denmark

Eligibility

Min Age
0 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-15
Primary Completion
2024-11-01
Completion
2025-11-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05639673 on ClinicalTrials.gov